Small Company Offering and Sale of Securities Without Registration (d)
22 Giugno 2021 - 10:59PM
Edgar (US Regulatory)
o
NoneEntity Type | 0001808805 | ARYA Sciences Acquisition Corp III |
x
Corporation
o
Limited Partnership
o
Limited Liability Company
o
General Partnership
o
Business Trust
o
Other |
Name of Issuer |
Nautilus Biotechnology, Inc. |
Jurisdiction of Incorporation/Organization |
DELAWARE |
|
Year of Incorporation/Organization |
|
o
| Over Five Years Ago |
|
x
| Within Last Five Years (Specify Year) | 2020 |
|
o
| Yet to Be Formed | |
2. Principal Place of Business and Contact Information |
Name of Issuer | |
Nautilus Biotechnology, Inc. | |
Street Address 1 | Street Address 2 |
425 PONTIUS AVE N, STE 202 | |
City | State/Province/Country | ZIP/Postal Code | Phone No. of Issuer |
SEATTLE | WASHINGTON | 98109 | 206-333-2001 |
Last Name | First Name | Middle Name |
Patel | Sujal | |
Street Address 1 | Street Address 2 |
c/o Nautilus Biotechnology, Inc. | 425 PONTIUS AVE N, STE 202 |
City | State/Province/Country | ZIP/Postal Code |
Seattle | WASHINGTON | 98109 |
Relationship: |
x
| Executive Officer |
x
| Director |
o
| Promoter |
Clarification of Response (if Necessary) |
| |
Last Name | First Name | Middle Name |
Mallick | Parag | |
Street Address 1 | Street Address 2 |
c/o Nautilus Biotechnology, Inc. | 425 PONTIUS AVE N, STE 202 |
City | State/Province/Country | ZIP/Postal Code |
Seattle | WASHINGTON | 98109 |
Relationship: |
x
| Executive Officer |
x
| Director |
o
| Promoter |
Clarification of Response (if Necessary) |
| |
Last Name | First Name | Middle Name |
Pande | Vijay | |
Street Address 1 | Street Address 2 |
c/o Nautilus Biotechnology, Inc. | 425 PONTIUS AVE N, STE 202 |
City | State/Province/Country | ZIP/Postal Code |
Seattle | WASHINGTON | 98109 |
Relationship: |
o
| Executive Officer |
x
| Director |
o
| Promoter |
Clarification of Response (if Necessary) |
| |
Last Name | First Name | Middle Name |
Nazem | Farzad | |
Street Address 1 | Street Address 2 |
c/o Nautilus Biotechnology, Inc. | 425 PONTIUS AVE N, STE 202 |
City | State/Province/Country | ZIP/Postal Code |
Seattle | WASHINGTON | 98109 |
Relationship: |
o
| Executive Officer |
x
| Director |
o
| Promoter |
Clarification of Response (if Necessary) |
| |
Last Name | First Name | Middle Name |
Posard | Matthew | |
Street Address 1 | Street Address 2 |
c/o Nautilus Biotechnology, Inc. | 425 PONTIUS AVE N, STE 202 |
City | State/Province/Country | ZIP/Postal Code |
Seattle | WASHINGTON | 98109 |
Relationship: |
o
| Executive Officer |
x
| Director |
o
| Promoter |
Clarification of Response (if Necessary) |
| |
Last Name | First Name | Middle Name |
Mowry | Anna | |
Street Address 1 | Street Address 2 |
c/o Nautilus Biotechnology, Inc. | 425 PONTIUS AVE N, STE 202 |
City | State/Province/Country | ZIP/Postal Code |
Seattle | WASHINGTON | 98109 |
Relationship: |
x
| Executive Officer |
o
| Director |
o
| Promoter |
Clarification of Response (if Necessary) |
| |
Last Name | First Name | Middle Name |
Epperly | Melissa | |
Street Address 1 | Street Address 2 |
c/o Nautilus Biotechnology, Inc. | 425 PONTIUS AVE N, STE 202 |
City | State/Province/Country | ZIP/Postal Code |
Seattle | WASHINGTON | 98109 |
Relationship: |
o
| Executive Officer |
x
| Director |
o
| Promoter |
Clarification of Response (if Necessary) |
| |
Last Name | First Name | Middle Name |
Altman | Michael | |
Street Address 1 | Street Address 2 |
c/o Nautilus Biotechnology, Inc. | 425 PONTIUS AVE N, STE 202 |
City | State/Province/Country | ZIP/Postal Code |
Seattle | WASHINGTON | 98109 |
Relationship: |
o
| Executive Officer |
x
| Director |
o
| Promoter |
Clarification of Response (if Necessary) |
| |
Last Name | First Name | Middle Name |
McIlwain | Matthew | S. |
Street Address 1 | Street Address 2 |
c/o Nautilus Biotechnology, Inc. | 425 PONTIUS AVE N, STE 202 |
City | State/Province/Country | ZIP/Postal Code |
Seattle | WASHINGTON | 98109 |
Relationship: |
o
| Executive Officer |
x
| Director |
o
| Promoter |
Clarification of Response (if Necessary) |
| |
Last Name | First Name | Middle Name |
Nelson | Nicholas | |
Street Address 1 | Street Address 2 |
c/o Nautilus Biotechnology, Inc. | 425 PONTIUS AVE N, STE 202 |
City | State/Province/Country | ZIP/Postal Code |
Seattle | WASHINGTON | 98109 |
Relationship: |
x
| Executive Officer |
o
| Director |
o
| Promoter |
Clarification of Response (if Necessary) |
| |
Last Name | First Name | Middle Name |
Sankar | Subra | |
Street Address 1 | Street Address 2 |
c/o Nautilus Biotechnology, Inc. | 425 PONTIUS AVE N, STE 202 |
City | State/Province/Country | ZIP/Postal Code |
Seattle | WASHINGTON | 98109 |
Relationship: |
x
| Executive Officer |
o
| Director |
o
| Promoter |
Clarification of Response (if Necessary) |
| |
Last Name | First Name | Middle Name |
Murphy | Matthew | |
Street Address 1 | Street Address 2 |
c/o Nautilus Biotechnology, Inc. | 425 PONTIUS AVE N, STE 202 |
City | State/Province/Country | ZIP/Postal Code |
Seattle | WASHINGTON | 98109 |
Relationship: |
x
| Executive Officer |
o
| Director |
o
| Promoter |
Clarification of Response (if Necessary) |
| |
o
| Agriculture | | Health Care |
o
| Retailing |
| Banking & Financial Services | |
o
| Biotechnology |
o
| Restaurants |
|
o
| Commercial Banking | |
o
| Health Insurance | | Technology |
|
o
| Insurance | |
o
| Hospitals & Physicians | |
o
| Computers |
|
o
| Investing | |
o
| Pharmaceuticals | |
o
| Telecommunications |
|
o
| Investment Banking | |
o
| Other Health Care | |
o
| Other Technology |
|
o
| Pooled Investment Fund
| | | | | Travel |
|
o
| Other Banking & Financial Services |
o
| Manufacturing | |
o
| Airlines & Airports |
| Real Estate | |
o
| Lodging & Conventions |
|
o
| Commercial | |
o
| Tourism & Travel Services |
|
o
| Construction | |
o
| Other Travel |
|
o
| REITS & Finance |
x
| Other |
|
o
| Residential | |
|
o
| Other Real Estate | |
o
| Business Services | |
| Energy | |
|
o
| Coal Mining | |
|
o
| Electric Utilities | |
|
o
| Energy Conservation | |
|
o
| Environmental Services | |
|
o
| Oil & Gas | |
|
o
| Other Energy | |
Revenue Range | Aggregate Net Asset Value Range |
o
| No Revenues |
o
| No Aggregate Net Asset Value |
o
| $1 - $1,000,000 |
o
| $1 - $5,000,000 |
o
| $1,000,001 - $5,000,000 |
o
| $5,000,001 - $25,000,000 |
o
| $5,000,001 - $25,000,000 |
o
| $25,000,001 - $50,000,000 |
o
| $25,000,001 - $100,000,000 |
o
| $50,000,001 - $100,000,000 |
o
| Over $100,000,000 |
o
| Over $100,000,000 |
x
| Decline to Disclose |
o
| Decline to Disclose |
o
| Not Applicable |
o
| Not Applicable |
6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply) |
o
| Rule 504(b)(1) (not (i), (ii) or (iii)) |
o
| Rule 505 |
o
| Rule 504 (b)(1)(i) |
x
| Rule 506(b) |
o
| Rule 504 (b)(1)(ii) |
o
| Rule 506(c) |
o
| Rule 504 (b)(1)(iii) |
o
| Securities Act Section 4(a)(5) |
|
o
| Investment Company Act Section 3(c) |
x
| New Notice | Date of First Sale | 2021-06-09 |
o
| First Sale Yet to Occur |
Does the Issuer intend this offering to last more than one year? |
o
| Yes |
x
| No |
9. Type(s) of Securities Offered (select all that apply) |
o
| Pooled Investment Fund Interests |
x
| Equity |
o
| Tenant-in-Common Securities |
o
| Debt |
o
| Mineral Property Securities |
o
| Option, Warrant or Other Right to Acquire Another Security |
o
| Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security |
o
| Other (describe) |
| |
10. Business Combination Transaction |
Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer? |
o
| Yes |
x
| No |
|
Clarification of Response (if Necessary) | |
|
Minimum investment accepted from any outside investor | $ 0 USD |
Recipient | Recipient CRD Number |
o
| None |
Jefferies LLC | 2347 |
(Associated) Broker or Dealer |
x
| None | (Associated) Broker or Dealer CRD Number |
x
| None |
| |
Street Address 1 | Street Address 2 |
520 Madison Avenue | |
City | State/Province/Country | ZIP/Postal Code |
New York | NEW YORK | 10022 |
State(s) of Solicitation |
x
| All States |
o
| Foreign/Non-US |
|
Recipient | Recipient CRD Number |
o
| None |
Goldman Sachs & Co. LLC | 361 |
(Associated) Broker or Dealer |
x
| None | (Associated) Broker or Dealer CRD Number |
x
| None |
| |
Street Address 1 | Street Address 2 |
200 West Street | |
City | State/Province/Country | ZIP/Postal Code |
New York | NEW YORK | 10282-2198 |
State(s) of Solicitation |
x
| All States |
o
| Foreign/Non-US |
|
13. Offering and Sales Amounts |
Total Offering Amount | $ 200000000 USD |
o
Indefinite |
Total Amount Sold | $ 200000000 USD | |
Total Remaining to be Sold | $ 0 USD |
o
Indefinite |
|
Clarification of Response (if Necessary) |
|
o
| Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, Number of such non-accredited investors who already have invested in the offering
| |
| Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering: | 38 |
15. Sales Commissions & Finders’ Fees Expenses |
Provide separately the amounts of sales commissions and finders' fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.
|
Sales Commissions | $ 2000000 USD |
o
| Estimate |
Finders' Fees | $ 0 USD |
o
| Estimate |
|
Clarification of Response (if Necessary) |
$1,000,000 in commission fees were paid to each Goldman Sachs & Co. LLC and Jefferies LLC. |
Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.
|
| $ 0 USD |
o
Grafico Azioni ARYA Sciences Acquistion... (NASDAQ:ARYA) Storico Da Apr 2024 a Mag 2024
Grafico Azioni ARYA Sciences Acquistion... (NASDAQ:ARYA) Storico Da Mag 2023 a Mag 2024
Notizie in Tempo Reale relative a ARYA Sciences Acquistion Corporation III (NASDAQ): 0 articoli recenti
Più Nautilus Biotechnology, Inc. Articoli Notizie
Le azioni che visualizzerai appariranno in questo riquadro, così potrai facilmente tornare alle quotazioni di tuo interesse.
|